Stock Alert for Orexigen Therapeutics Inc. (OREX)
  • Stock Alert for Dendreon Corp. (DNDN)
  • Stock Alert for Aeterna Zentaris Inc. (AEZS)
  • " />

    Stock Alert for Oncothyreon Inc. (ONTY)

    Oncothyreon Inc. (ONTY) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company’s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. ONTY’s lead product candidate is Stimuvax, a cancer vaccine in phase III development for non-small cell lung cancer (NSCLC). ONTY has an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax.

    Share Statistics (21-July-11) FY2009 FY2010 % Chg Q12010 Q12011 % Chg
    Symbol ONTY Revenue, $Mn 2.08 0.02 -99.0% 0.01 0.14 1300.0%
    Current price $10.13 Gross marg. 100.0% 100.0% 100.0% 100.0% 0.0%
    52wk Range: $2.99-$11.59 Oper. margin -108244.4% -4049.7%
    Avg Vol (3m): 1,381,720 Net margin -827.9% -78100.0% 9333.5% -7700.0% -5085.7% -34.0%
    Market Cap. $429.26
    Shares Outstanding 41.60 EPS, $ -0.76 -0.58 -23.7% -0.03 -0.24 700.0%

    Source:, SEC Filings.

    Recent News

    Shares of ONTY rallied more than 15% on Wednesday after a Seeking Alpha report suggested that the small-cap cancer drug developer could report a successful phase III trial of Stimuvax, which is indicated for Stage 3 non-small cell lung cancer. Currently nearing the end of its phase III study, the drug is suggested to have an “overwhelming” 90%+ chance of success. Seeking Alpha believes ONTY investors will “at least” triple their investment on a successful clinical trial.

    ONTY climbed higher on Thursday and set a new 52 week high of $11.59.  Over 4.80 million shares have traded hands during the session, versus the 10-day average volume of 2.09 million.  ONTY is currently trading above its 50-day moving average of $8.02 and above its 200-day moving average of $4.95.  The current market capitalization stands at $429.26 million and shares outstanding is at 41.60 million shares.

    Financial Summary

    ONTY reported a net loss from operations of $5.9 million for the first quarter of 2011, up from $5.4 million in the first quarter of 2010.  The Company attributed the result to increased research and development expenses, offset by a decrease in general and administrative expenses.

    For the quarter ended March 31, 2011, net loss was $7.1 million, or $0.24 per basic and diluted share, up from the prior year quarter’s net loss of $0.8 million, or $0.03 per basic and diluted share. The increase in net loss was primarily the result of a non-cash expense of $1.5 million as a result of an increase in fair value of warrant liability in the quarter ended March 31, 2011, compared with a $4.6 million decrease in fair value of warrant liability in the quarter ended March 31, 2010.

    ONTY’s cash, cash equivalents and short-term investments totaled $29.0 million as of March 31, 2011.  That compares to $28.9 million at the end of 2010, an increase of $0.1 million attributable to $5.0 million in funding from the initial term loan with General Electric Capital Corp., offset by cash used in operations and capital expenditures during the quarter.

    Financial Strength (21-July-2011)




    S&P 500

    Quick Ratio (MRQ) 2.95 2.07 0.69
    Current Ratio (MRQ) 10.03 3.87 2.59 1.03
    LT Debt to Equity (MRQ) 34.07 20.38 22.49 125.35
    Total Debt to Equity (MRQ) 40.31 24.22 27.11 164.62
    Interest Coverage (TTM) 6.18 1.62 19.08

    Source:, SEC Filings.

    Analyst Consensus

    This is the consensus forecast among four polled investment analysts. Against the Oncothyreon Inc company.

    Analyst Detail






    No Opinion

    Latest 2 2 0 0 0 0
    4 weeks ago 2 2 0 0 0 0
    2 months ago 1 3 0 0 0 0
    3 months ago 1 3 0 0 0 0
    Last year 1 1 0 0 0 0


    Consensus Estimates Analysis

    # of Estimates




    1 Year Ago

    SALES (in millions)
    Quarter Ending Sep-11 4 0.95 3.82 0.00 0.26
    Quarter Ending Dec-11 4 0.95 3.82 0.00 0.26
    Year Ending Dec-11 5 0.51 2.00 0.10 1.03
    Year Ending Dec-12 4 9.30 20.00 0.00 2.07
    EARNINGS (per share)
    Quarter Ending Sep-11 4 -0.16 -0.15 -0.18 -0.20
    Quarter Ending Dec-11 4 -0.16 -0.15 -0.17 -0.20
    Year Ending Dec-11 5 -0.67 -0.63 -0.76 -0.77
    Year Ending Dec-12 4 -0.42 -0.22 -0.64 -0.81

    Technical Analysis


    ONTY is above the upper Bollinger Band, implying that it is currently extended from its recent trend.

    The MACD for ONTY currently indicates a strong bullish signal for two reasons. First, the MACD is above the signal line, a 9-day moving average. Second, the MACD is above 0, which implies that the underlying moving averages are trending higher.

    Comparative Analysis

    Company Name Ticker Price per Mrkt. Cap. P/E P/S
    July21-2011 symbol Share, $ $ Mn 2011 2012 2011 2012
    Exelixis Inc. EXEL 8.70 1.11B n/a n/a 7.35 7.12
    Enzon Pharmaceuticals Inc. ENZN 10.41 557.42M 94.64 26.69 8.04 7.61
    GlaxoSmithKline plc GSK 44.04 112.02B 11.93 11.04 2.55 2.45
    Biotechnology  Median       19.29 n/a 1.45 n/a
    Oncothyreon Inc. ONTY 10.13 430.72M n/a n/a n/a 42.14

    Source: Thomson Financial

    DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

    The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

    Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

    Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

    Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

    We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

    To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

    We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at



     [1]HTML: <NOSCRIPT>

     [2]HTML: </NOSCRIPT>

    Leave a Reply

    Your email address will not be published. Required fields are marked *